David K Zielke, MD | |
4315 Diplomacy Dr, Anchorage, AK 99508-5926 | |
(907) 729-1301 | |
Not Available |
Full Name | David K Zielke |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 10 Years |
Location | 4315 Diplomacy Dr, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063822831 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 162620 (Alaska) | Primary |
207RC0200X | Internal Medicine - Critical Care Medicine | 162620 (Alaska) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Alaska Native Medical Center | Anchorage, AK | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Alaska Native Tribal Health Consortium | 6709780265 | 457 |
News Archive
From a survey of faculty physicians, resident physicians and medical students, researchers found that while nearly all respondents indicated that they would disclose a hypothetical error, less than half reported having disclosed an actual minor or major medical error.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have found that among obese people who had lost considerable weight, those with high insulin levels-a marker of insulin resistance in the body-were the most likely to experience better blood vessel function following the weight loss. These findings appear online in the Journal of the American College of Cardiology.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.
For nurses who work long hours or other "adverse work schedules," the risk of obesity is related to lack of opportunity for exercise and sleep, suggests a study in the August issue of Journal of Occupational and Environmental Medicine, the official publication of the American College of Occupational and Environmental Medicine (ACOEM).
EKF, launched the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.
› Verified 2 days ago
Entity Name | Alaska Native Tribal Health Consortium |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1437189339 PECOS PAC ID: 6709780265 Enrollment ID: O20031125000772 |
News Archive
From a survey of faculty physicians, resident physicians and medical students, researchers found that while nearly all respondents indicated that they would disclose a hypothetical error, less than half reported having disclosed an actual minor or major medical error.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have found that among obese people who had lost considerable weight, those with high insulin levels-a marker of insulin resistance in the body-were the most likely to experience better blood vessel function following the weight loss. These findings appear online in the Journal of the American College of Cardiology.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.
For nurses who work long hours or other "adverse work schedules," the risk of obesity is related to lack of opportunity for exercise and sleep, suggests a study in the August issue of Journal of Occupational and Environmental Medicine, the official publication of the American College of Occupational and Environmental Medicine (ACOEM).
EKF, launched the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
David K Zielke, MD 1 Medical Center Dr, Dartmouth-hitchcock Graduate Medical Education, Lebanon, NH 03756-1000 Ph: () - | David K Zielke, MD 4315 Diplomacy Dr, Anchorage, AK 99508-5926 Ph: (907) 729-1301 |
News Archive
From a survey of faculty physicians, resident physicians and medical students, researchers found that while nearly all respondents indicated that they would disclose a hypothetical error, less than half reported having disclosed an actual minor or major medical error.
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have found that among obese people who had lost considerable weight, those with high insulin levels-a marker of insulin resistance in the body-were the most likely to experience better blood vessel function following the weight loss. These findings appear online in the Journal of the American College of Cardiology.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.
For nurses who work long hours or other "adverse work schedules," the risk of obesity is related to lack of opportunity for exercise and sleep, suggests a study in the August issue of Journal of Occupational and Environmental Medicine, the official publication of the American College of Occupational and Environmental Medicine (ACOEM).
EKF, launched the Altair™ 240 clinical chemistry analyzer to the European market at Medica 2015, Düsseldorf, 16-19th November.
› Verified 2 days ago
Andrea Caballero, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3220 Providence Dr Ste E3-080, Anchorage, AK 99508 Phone: 907-375-8785 Fax: 907-375-8788 | |
Daryl M. Mcclendon, M.D., P.C. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3851 Piper Street, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Dr. Loretta Leih-sheng Lee, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4001 Dale St, Suite 210, Anchorage, AK 99508 Phone: 907-929-5880 Fax: 907-929-5882 | |
Dr. Richard Merle Farleigh, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 4120 Laurel St, Suite 202, Anchorage, AK 99508 Phone: 907-561-4293 | |
Alexis Leandro Delgado, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4300 B St, Suite 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Geronimo Sahagun, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2841 Debarr Road, Suite 50, Anchorage, AK 99508 Phone: 907-276-2811 Fax: 907-276-2810 | |
Dr. Tram Phuong Chu, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3200 Providence Dr, Suite B111, Anchorage, AK 99508 Phone: 907-212-7890 Fax: 907-212-2374 |